Vasomotor Symptoms, Metabolic Syndrome, and Cardiovascular Risks

  • Pauliina TuomikoskiEmail author
  • Hanna Savolainen-Peltonen


Vasomotor symptoms (VMS), such as hot flushes and night sweats, are common during the menopausal transition. Although the underlying etiopathology behind vasomotor symptoms is not fully identified, they have been associated with an overdrive of the sympathetic nervous system, which in turn may result in altered vascular function, changes in blood pressure (BP) and lipids, and the development of insulin resistance. Metabolic syndrome (MetS) is a cluster of closely related risk factors for cardiovascular disease (CVD): elevated BP, dyslipidemia, hyperglycemia, and central obesity. Thus, VMS and MetS share a common nominator, sympathetic overactivity. As of lately, due to these associations, the presence of VMS has gained interest as a possible risk factor for CVD. However, the results are mixed, and interpretation of findings is further complicated by the fact that some researchers distinguish between hot flushes and night sweats and others do not. In this chapter we present the most recent data on the possible relations between menopausal vasomotor symptoms, the components of metabolic syndrome, and cardiovascular disease.


Vasomotor symptoms Hot flushes Night sweats Menopause Metabolic syndrome Cardiovascular disease 


  1. 1.
    Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol. 2014;142:115–20.CrossRefGoogle Scholar
  2. 2.
    Schlaich M, Straznicky N, Lambert E, Lambert G. Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol. 2015;3:148–57.CrossRefGoogle Scholar
  3. 3.
    Vongpatanasin W. Autonomic regulation of blood pressure in menopause. Semin Reprod Med. 2009;27:338–45.CrossRefGoogle Scholar
  4. 4.
    Lambert E, Straznicky N, Sari CI, et al. Dyslipidemia is associated with sympathetic nervous activation and impaired endothelial function in young females. Am J Hypertens. 2013;26:250–6.CrossRefGoogle Scholar
  5. 5.
    Hitchcock CL, Elliott TG, Norman EG, Tajic V, Teede H, Prior JC. Hot flushes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women. Menopause. 2012;19:1208–14.CrossRefGoogle Scholar
  6. 6.
    Tuomikoski P, Haapalahti P, Ylikorkala O, Mikkola TS. Vasomotor hot flushes and 24-hour ambulatory blood pressure in recently post-menopausal women. Ann Med. 2010;42:216–22.CrossRefGoogle Scholar
  7. 7.
    Silveira JS, Clapauch R, Souza MD, Bouskela E. Hot flashes: emerging cardiovascular risk factors in recent and late postmenopause and their association with higher blood pressure. Menopause. 2016;23:846–55.CrossRefGoogle Scholar
  8. 8.
    Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the study of Women’s health across the nation. Obstet Gynecol Clin North Am. 2011;38:489–501.CrossRefGoogle Scholar
  9. 9.
    Jackson EA, El Khoudary SR, Crawford SL, Matthews K, Joffe H, Chae C, et al. Hot flash frequency and blood pressure: data from the study of Women’s health across the nation. J Womens Health (Larchmt). 2016;25:1204–9.CrossRefGoogle Scholar
  10. 10.
    Thurston RC, El Khoudary SR, Sutton-Tyrrell K, Crandall CJ, Gold EB, Sternfeld B, et al. Vasomotor symptoms and lipid profiles in women transitioning through menopause. Obstet Gynecol. 2012;119:753–61.CrossRefGoogle Scholar
  11. 11.
    Franco OH, Muka T, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, Kavousi M. Vasomotor symptoms in women and cardiovascular risk markers: systematic review and meta-analysis. Maturitas. 2015;81:353–61.CrossRefGoogle Scholar
  12. 12.
    Ryu KJ, Park HT, Kwon DH, Yang KS, Kim YJ, et al. Vasomotor symptoms and metabolic syndrome in Korean postmenopausal women. Menopause. 2015;22:1239–45.CrossRefGoogle Scholar
  13. 13.
    van Dijk GM, Maneva M, Colpani V, Dhana K, Muka T, Jaspers L, et al. The association between vasomotor symptoms and metabolic health in peri- and postmenopausal women: a systematic review. Maturitas. 2015;80:140–7.CrossRefGoogle Scholar
  14. 14.
    Tuomikoski P, Savolainen-Peltonen H. Vasomotor symptoms and metabolic syndrome. Maturitas. 2017;97:61–5.CrossRefGoogle Scholar
  15. 15.
    Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629–36.CrossRefGoogle Scholar
  16. 16.
    Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2007;92:895–901.CrossRefGoogle Scholar
  17. 17.
    Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32:949–58.CrossRefGoogle Scholar
  18. 18.
    Abdulnour J, Doucet E, Brochu M, Lavoie JM, Strychar I, Rabasa-Lhoret R, et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa new emerging team group study. Menopause. 2012;19:760–7.CrossRefGoogle Scholar
  19. 19.
    Gallicchio L, Visvanathan K, Miller SR, Babus J, Lewis LM, Zacur H, et al. Body mass, estrogen levels, and hot flashes in midlife women. Am J Obstet Gynecol. 2005;193:1353–60.CrossRefGoogle Scholar
  20. 20.
    Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006;96:1226–35.CrossRefGoogle Scholar
  21. 21.
    Thurston RC, Sowers MR, Sutton-Tyrrell K, Everson-Rose SA, Lewis TT, Edmundowicz D, et al. Abdominal adiposity and hot flashes among midlife women. Menopause. 2008;15:429–34.CrossRefGoogle Scholar
  22. 22.
    Thurston RC, Chang Y, Mancuso P, Matthews KA. Adipokines, adiposity, and vasomotor symptoms during the menopause transition: findings from the study of Women’s health across the nation. Fertil Steril. 2013;100:793–800.CrossRefGoogle Scholar
  23. 23.
    Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1–2):69–78.CrossRefGoogle Scholar
  24. 24.
    Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci U S A. 1999;96:7047–52.CrossRefGoogle Scholar
  25. 25.
    Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci. 2002;967:379–88.CrossRefGoogle Scholar
  26. 26.
    Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015;2015:341583.CrossRefGoogle Scholar
  27. 27.
    Thurston RC, El Khoudary SR, Sutton-Tyrrell K, Crandall CJ, Sternfeld B, Joffe H, et al. Vasomotor symptoms and insulin resistance in the study of women’s health across the nation. J Clin Endocrinol Metab. 2012;97:3487–94.CrossRefGoogle Scholar
  28. 28.
    Lee SW, Jo HH, Kim MR, Kwon DJ, You YO, Kim JH. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet. 2012;285:541–8.CrossRefGoogle Scholar
  29. 29.
    Gast GC, Samsioe GN, Grobbee DE, Nilsson PM, van der Schouw YT. Vasomotor symptoms, estradiol levels and cardiovascular risk profile in women. Maturitas. 2010;66:285–90.CrossRefGoogle Scholar
  30. 30.
    Kwon DH, Lee JH, Ryu KJ, Park HT, Kim T. Vasomotor symptoms and the homeostatic model assessment of insulin-resistance in Korean postmenopausal women. Obstet Gynecol Sci. 2016;59:45–9.CrossRefGoogle Scholar
  31. 31.
    Thurston RC, Sutton-Tyrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease. Findings from the study of women’s health across the nation heart study. Circulation. 2008;118:1234–40.CrossRefGoogle Scholar
  32. 32.
    Thurston RC, Sutton-Tyrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA. Hot flashes and carotid intima media thickness among midlife women. Menopause. 2011;18:352–8.CrossRefGoogle Scholar
  33. 33.
    Thurston RC, El Khoudary SR, Tepper PG, et al. Trajectories of vasomotor symptoms and carotid intima media thickness in the study of women’s health across the nation. Stroke. 2016;47:12–7.CrossRefGoogle Scholar
  34. 34.
    Tuomikoski P, Ebert P, Haapalahti P, Hautamäki H, Rönnback M, Ylikorkala O, et al. Evidence for a role of hot flushes in vascular function in recently postmenopausal women. Obstet Gynecol. 2009;113:902–8.CrossRefGoogle Scholar
  35. 35.
    Wolff EF, He Y, Black DM, Brinton EA, Budoff MJ, Cerdars MI, et al. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). Fertil Steril. 2013;99:1385–91.CrossRefGoogle Scholar
  36. 36.
    Allison MA, Manson JE, Aragaki A, Langer RD, Rossouw J, Curb D, et al. Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause. 2010;17:1136–45.CrossRefGoogle Scholar
  37. 37.
    Tuomikoski P, Haapalahti P, Sarna S, Ylikorkala O, Mikkola TS. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: a placebo-controlled trial on post-menopausal hormone therapy. Ann Med. 2010;42:334–43.CrossRefGoogle Scholar
  38. 38.
    Ferri LA, Morici N, Bassanelli G, Fraqnco N, Misuraca L, Lenatti L, et al. History of vasomotor symptoms, extent of coronary artery disease, and clinical outcomes after acute coronary syndrome in postmenopausal women. Menopause. 2018;25:635–40.CrossRefGoogle Scholar
  39. 39.
    Herber-Gast GCM, Brown WJ, Mishra GD. Hot flushes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study. BJOG. 2015;122:1560–7.CrossRefGoogle Scholar
  40. 40.
    Svartberg J, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms and mortality: the Rancho Bernardo study. Menopause. 2009;16:888–91.CrossRefGoogle Scholar
  41. 41.
    Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. Study of women’s health across the nation. JAMA Intern Med. 2015;175:531–9.CrossRefGoogle Scholar
  42. 42.
    Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab. 2015;100:4588–94.CrossRefGoogle Scholar
  43. 43.
    Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, et al. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause. 2018;25:375–9.PubMedGoogle Scholar
  44. 44.
    Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310:1353–68.CrossRefGoogle Scholar
  45. 45.
    Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al.; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49–57.CrossRefGoogle Scholar
  46. 46.
    Buber J, Mathew J, Moss AJ, Hall WJ, Barsheshet A, McNitt S, et al. Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2. Circulation. 2011;123:2784–91.CrossRefGoogle Scholar
  47. 47.
    Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2009;16:639–43.CrossRefGoogle Scholar
  48. 48.
    Szmuilowicz ED, Manson JE, Rossouw JE, Howard BV, Margolis KL, Greep NC, et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause. 2011;18:603–10.CrossRefGoogle Scholar
  49. 49.
    Thurston RC, Johnson BD, Shufelt CL, et al. Menopausal symptoms and cardiovascular disease mortality in the women’s ischemia syndrome evaluation (WISE). Menopause. 2017;24:126–32.CrossRefGoogle Scholar
  50. 50.
    Freedman RR. Objective or subjective measurement of hot flashes in clinical trials: quo vadis. Maturitas. 2010;67:99–100.CrossRefGoogle Scholar
  51. 51.
    Fu P, Matthews KA, Thurston RC. How well do different measurement modalities estimate the number of vasomotor symptoms? Findings from the study of women’s health across the nation FLASHES study. Menopause. 2014;21:124–30.CrossRefGoogle Scholar
  52. 52.
    Miller VM, Kling JM, Files JA, Joyner MJ, Kapoor E, Moyer AM, et al. What’s in a name: are menopausal “hot flashes” a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause. 2018;25:700–3.CrossRefGoogle Scholar
  53. 53.
    Thurston RC, Chang Y, Barinas-Mitchell E, Jennings JR, von Känel R, Landsittel DP, et al. Menopausal hot flashes and carotid intima media thickness among midlife women. Stroke. 2016;47:2910–5.CrossRefGoogle Scholar
  54. 54.
    Thurston RC, Chang Y, Barinas-Mitchell E, Jennings JR, von Känel R, Landsittel DP, et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause. 2017;24:886–93.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Pauliina Tuomikoski
    • 1
    • 2
    Email author
  • Hanna Savolainen-Peltonen
    • 1
    • 3
  1. 1.University of HelsinkiHelsinkiFinland
  2. 2.Eira Hospital and Medical CenterHelsinkiFinland
  3. 3.Department of Obstetrics and GynecologyHelsinki University HospitalHelsinkiFinland

Personalised recommendations